UNSPSC 51401569: Midazolam hydrochloride

This classification denotes an anesthesia adjuvant, anti-anxiety agent, hypnotic, and sedative with the molecular formula C18H13ClFN3.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier W7TTW573JJ, chemically known as 8-chloro-6-(o-fluorophenyl)-1-methyl-4h-imidazo(1,5-a)(1,4)benzodiazepine but more generally known as midazolam hydrochloride, which bears US NIH Compound Identifier 4192.

UNSPSC 51401569 Midazolam hydrochloride is a Commodity code that in recent state and local procurement covers the supply of pharmaceutical products, including sedatives and emergency medications, alongside complementary health and safety items. The scope of work encompasses bulk purchase and delivery of branded or generic pharmaceutical products to support community health initiatives, emergency response programs, and state pharmacy benefit systems. Issuing bodies include county health departments, state health and human services commissions, and cooperative purchasing alliances serving multiple state and local jurisdictions. Solicitations under this code reflect a mix of direct purchase contracts for specific medications and broader multi-source pharmaceutical supply agreements that establish vendor relationships for ongoing distribution to government facilities.

Recent activity spans Florida, Minnesota, and Texas. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with quarterly deliveries to the Seminole County Community Health Building, with bids due July 26, 2023, as a two-year contract with a one-year renewal option. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued an RFP (S1070000015802) in January 2026 for generic multi-source pharmaceuticals and OTC products across participating state and local government facilities in Minnesota and Oregon, with proposals due March 26, 2026 and awarded vendors effective July 1, 2026; evaluation weighted price competitiveness at 75 percent and required vendors to maintain relationships with authorized wholesalers including AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co., LLC. The Texas Health and Human Services Commission released an RFI (HHS0017013) in April 2026 to gather market intelligence on direct-to-manufacturer prescription programs and vendor capabilities for implementing a Therapeutic Pharmacy Initiative without traditional pharmacy benefit manager intermediaries, representing preliminary planning for a subsequent formal solicitation.